 Clinical data update on zenocutuzumab selected for oral presentation at ASCO MCLA-145 clinical update planned for 2H21 MCLA-129 first patient dosed in phase 12 trial Cecile Geuijen, Ph.D., promoted to Chief Scientific Officer 